Media Contact: Tracy Vineis media@apellis.com (617) 420-4839
- March 31, 2026 Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
- March 2, 2026 Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
- February 24, 2026 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
- February 23, 2026 Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
- February 19, 2026 Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
- February 10, 2026 Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
- January 12, 2026 Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
- January 5, 2026 Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- December 3, 2025 The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
- November 25, 2025 Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
Displaying 1 - 10 of 341